Expanding the range of kidney protection by SGLT2i | Beatriz Fernandez Fernandez, MD, PhD

In this ERA Symposium video, Dr. Beatriz Fernandez Fernandez, MD, PhD, delves into the transformative role of SGLT2 inhibitors in chronic kidney disease (CKD) management. Originally known for their effectiveness in treating type 2 diabetes mellitus (T2DM), SGLT2 inhibitors have rapidly evolved to address a wider range of renal diseases. Beyond glycemic control, these drugs offer significant benefits in improving renal hemodynamics and reducing tubulointerstitial injury, making them a powerful tool in combating both diabetic and non-diabetic kidney conditions.
Dr. Fernandez discusses the paradigm shift these medications have brought to CKD treatment and explores their expanding role in cardio-kidney-metabolic disorders. With promising results from recent randomized clinical trials, SGLT2 inhibitors are becoming a cornerstone in CKD care. The video also highlights future directions, including the integration of SGLT2 inhibitors into CKD treatment guidelines and their potential as the optimal therapy for a broad patient population.
Don't miss this insightful presentation that sheds light on the latest advancements in kidney protection and the expanding therapeutic potential of SGLT2 inhibitors.